Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: A reflection from MTOPS

Current Opinion in Urology

Volumn 14, Issue 1, 2004, Pages 17-20

  Desgrandchamps, François ^a,b  

^a Hospital of Saint Louis   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

5 reductase inhibitors; Alphablockers; Benign prostatic hyperplasia (BPH); Combination therapy; Medical treatment

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN; STEROID 5ALPHA REDUCTASE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ASTHENIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DYSPNEA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HIGH RISK PATIENT; HUMAN; LIBIDO DISORDER; ORGAN SIZE; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; REVIEW; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TREATMENT OUTCOME; AGE; AGED; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; HOSPITALIZATION; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; AGE FACTORS; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME; URODYNAMICS;

EID: 2342578089     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200401000-00004     Document Type: Review

References (7)

1. Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998; 34:169-75.
2. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335:533-539.
3. Kirby RS, Roehrborn C, Boyle P, et al. The Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61:119-126. Study comparing doxazosin or finasteride alone with a placebo or a combination of both drugs. More than 1000 patients were included in this 1-year study.
4. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338:557-563.
5. Bautista OM, Kusek JW, Nyberg LM, et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 2003; 24:224-243. The design of the MTOPS study.
6. Mc Connell JD. The impact of medical therapy on the clinical progression of BPH: results of the MTOPS trial [abstract]. J Urol 2002; 167:1042. Preliminary report of the MTOPS study results: 3047 BPH patients were randomized into four arms to receive either doxazosin (4 or 8 mg) alone, finasteride (5 mg) alone, a placebo or a combination of both drugs.
7. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170:530-547. The only post-MTOPS practical guidelines available for BPH.